• Wave Life Sciences has reported its fourth-quarter and full-year 2025 results, with quarterly revenue falling to US$17.24 million from US$83.75 million and the company moving from a net income of US$29.25 million to a net loss of US$53.18 million, while also outlining progress across its RNA-based obesity and alpha-1 antitrypsin deficiency programs.
• Despite wider losses, Wave highlighted interim obesity and alpha-1 antitrypsin deficiency data, a cash position of US$602.10 million funding operations into 2028, and an expanded GSK collaboration that could eventually deliver up to US$2.80 billion in milestones and royalties, underscoring the scale of its partnered pipeline.
• We’ll now examine how Wave’s positive WVE-007 obesity data and extended cash runway into 2028 affect its existing investment narrative.

AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Wave Life Sciences Investment Narrative Recap

To own Wave Life Sciences, you have to believe its RNA platforms in obesity and AATD can convert promising early data into approved products before the cash runs down. The latest results deepen losses but do not change the near term focus: upcoming WVE-007 obesity and WVE-006 AATD data remain the key catalysts, while ongoing high cash burn and reliance on partner and equity funding remain the central risks.

The most relevant update here is Wave’s report of US$602.10 million in cash and equivalents, expected to fund operations into 2028. This extended runway helps support the path through planned WVE-007 Phase 2a obesity studies and additional WVE-006 readouts, giving management time to generate the data that will ultimately decide whether the current pipeline can support a more durable, less partnership dependent revenue base.

Yet, against these encouraging data updates, investors should also be aware of the growing tension between Wave’s widening net losses and its dependence on future fundraising...

Wave Life Sciences' narrative projects $177.5 million revenue and $41.2 million earnings by 2028.

Uncover how Wave Life Sciences' forecasts yield a $33.38 fair value, a 140% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic, assuming revenue could reach about US$471.3 million and earnings US$72.8 million by 2028, while this latest earnings report may prompt you to rethink how realistic that outcome looks compared with the very real risks around cash burn and clinical execution.

Explore 3 other fair value estimates on Wave Life Sciences - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Wave Life Sciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Wave Life Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Wave Life Sciences' overall financial health at a glance.

No Opportunity In Wave Life Sciences?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.